MM120

DRUG3 trials

Sponsors

Mind Medicine Inc., Definium Therapeutics US, Inc.

Conditions

ADHDAnxiety GeneralizedAttention Deficit DisorderGeneralized Anxiety Disorder (GAD)

Phase 2

Safety and Efficacy of Low Dose MM120 for ADHD Proof of Concept Trial

CompletedNCT05200936

Definium Therapeutics US, Inc.ADHD, Attention Deficit Disorder

Start: 2021-12-17End: 2023-12-04Updated: 2026-02-27

A Dose-Finding Study of MM120 (LSD D-Tartrate) for the Treatment of Anxiety Symptoms

CompletedNCT05407064

Definium Therapeutics US, Inc.Anxiety Generalized

Start: 2022-08-24End: 2023-11-27Updated: 2026-02-27

Phase 3

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, 12-Week Study (Part A) with a 40 Week Open-Label Extension (Part B) Evaluating the Efficacy and Safety of Oral MM120 Compared to Placebo in the Treatment of Adults with Generalized Anxiety Disorder - Panorama

RecruitingCTIS2024-513572-17-00

Mind Medicine Inc.Generalized Anxiety Disorder (GAD)

Start: 2025-08-20Target: 201Updated: 2025-08-29

Related Papers

Effects of repeated low-dose LSD on neuropsychological functioning in adults with ADHD: a randomized placebo-controlled study

Psychopharmacology2026-06-20

Single Treatment With MM120 (Lysergide) in Generalized Anxiety Disorder: A Randomized Clinical Trial.

2025-10-01

MM120 (lysergide) in a controlled clinical setting: treatment of generalized anxiety disorder without co-occurring psychotherapeutic intervention

European Psychiatry2025-04-011 citations

Safety and Efficacy of Repeated Low-Dose LSD for ADHD Treatment in Adults

JAMA Psychiatry2025-03-197 citations